Herranz-Antolín Sandra, Álvarez-de Frutos Visitación, Torralba Miguel
Sección de Endocrinología y Nutrición, Hospital Universitario de Guadalajara, Guadalajara, España.
Sección de Endocrinología y Nutrición, Hospital Universitario de Guadalajara, Guadalajara, España.
Endocrinol Diabetes Nutr (Engl Ed). 2018 Apr;65(4):220-228. doi: 10.1016/j.endinu.2017.11.006. Epub 2018 Feb 1.
To assess the degree of metabolic control and hypoglycemic treatments in a cohort of patients with type 2 diabetes mellitus (T2DM) after evaluation in an endocrinology clinic.
A prospective cohort study on 465 patients with T2DM who were not being monitored at an endocrinology clinic. Blood glucose control data and treatments received were recorded at an initial visit and after 26 weeks of follow-up.
Baseline glycosylated hemoglobin (HbA1c) level was 8.3±1.8%, as compared to 6.6±0.9% after 26 weeks of follow-up (P<.0001). The proportion of patients with HbA1c levels <7% increased from 33.1% to 71.3% (P<.0001). In 59.9% of patients, a decrease ≥0.8% in HbA1c was seen. In the multivariate analysis, variables predicting for an improvement in the degree of metabolic control were older age (OR 1.038; 95%CI 1-1.07; P=.041), higher baseline HbA1c values (OR 5.51; 95%CI 3.4-9; P<.0001), T2DM duration <5 years (OR 4.63; 95%CI 1.6-13.3; P=.005), and change in hypoglycemic treatment (OR 2.77, 95%CI 1.1-6.9; P=.03). Hypoglycemic therapy was changed in 75.1% of study patients with T2DM. After 26 weeks of follow-up, decreases were seen in both the proportion of patients who receiveding no treatment (from 7% to 0.3%, P<.0001) and the proportions of patients on oral antidiabetic therapy (60.9% vs 55.5%, P=.003) and insulin (10.5% vs 6.2%, P=.021). However, the proportion of patients receiving insulin combined with oral antidiabetic drugs increased from 21.1% to 38% (P<.0001).
An improved metabolic control was seen in this cohort of patients with T2DM after their evaluation in an endocrinology clinic. However, HbA1c levels <7% were not achieved in 28.7% of patients, which shows the difficulty to achieve adequate control in clinical practice.
在一组2型糖尿病(T2DM)患者在内分泌科门诊接受评估后,评估其代谢控制程度和降糖治疗情况。
对465例未在内分泌科门诊接受监测的T2DM患者进行一项前瞻性队列研究。在初次就诊时及随访26周后记录血糖控制数据和接受的治疗。
基线糖化血红蛋白(HbA1c)水平为8.3±1.8%,随访26周后为6.6±0.9%(P<0.0001)。HbA1c水平<7%的患者比例从33.1%增至71.3%(P<0.0001)。59.9%的患者HbA1c下降≥0.8%。在多变量分析中,预测代谢控制程度改善的变量为年龄较大(比值比[OR]1.038;95%置信区间[CI]1 - 1.07;P = 0.041)、基线HbA1c值较高(OR 5.51;95%CI 3.4 - 9;P<0.0001)、T2DM病程<5年(OR 4.63;95%CI 1.6 - 13.3;P = 0.005)以及降糖治疗的改变(OR 2.77,95%CI 1.1 - 6.9;P = 0.03)。75.1%的T2DM研究患者改变了降糖治疗。随访26周后,未接受治疗的患者比例(从7%降至0.3%,P<0.0001)、接受口服降糖药治疗的患者比例(60.9%对55.5%,P = 0.003)和接受胰岛素治疗的患者比例(10.5%对6.2%,P = 0.021)均下降。然而,接受胰岛素联合口服降糖药治疗的患者比例从21.1%增至38%(P<0.0001)。
这组T2DM患者在内分泌科门诊评估后代谢控制得到改善。然而,28.7%的患者未达到HbA1c水平<7%,这表明在临床实践中实现充分控制存在困难。